April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
March 2025 in “FEBS Journal” Epiprofin suppresses parathyroid hormone gene activity, helping regulate calcium levels and could be a treatment target for hyperparathyroidism.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
June 1982 in “Revista Colombiana de Obstetricia y Ginecología” El acetato de ciproterona trata problemas androgénicos como hirsutismo, acné, seborrea y alopecia con diferentes dosis y combinaciones.
January 2005 in “Journal of Elinical Research” The two finasteride preparations are bioequivalent.
19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
60 citations
,
January 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying a specific inhibitor lightens skin and hair color.
33 citations
,
June 2007 in “Gene Expression Patterns” CTIP2 may help in skin development and maintenance.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
January 2009 in “Lishizhen Medicine and Materia Medica Research” Urtica fissa extract can inhibit 5α-reductase activity.
December 2023 in “International Journal of Dermatology”
15 citations
,
February 2021 in “Scientific Reports” RNA aptamers can specifically block FGF5-related cell growth, potentially treating related diseases or hair disorders.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking a key energy pathway in human hair follicles can trigger stress responses that stop cell growth.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
January 2015 in “Zurich Open Repository and Archive (University of Zurich)” The supplement did not work better than a placebo for hair loss in women over 60.
8 citations
,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
25 citations
,
November 2015 in “Journal of Ethnopharmacology” Certain Chinese herbs, especially Cacumen platycladi, can promote hair regrowth and reduce hair loss-related hormone levels in mice.
22 citations
,
September 2003 in “Journal of Investigative Dermatology” New mutations in the EBP gene cause CDPX2, affecting bones, skin, eyes, and hair, with females generally less affected than males.
January 2019 in “Arabian Journal of Chemistry” Method found to accurately identify finasteride impurities using liquid chromatography.
January 2006 in “Guangzhou Chemistry” The new method for making Finasteride is cheaper and safer for large-scale production.
6 citations
,
March 2005 in “The Journal of Urology” 2 citations
,
January 2007 in “edoc (University of Basel)” Piper cubeba and Aquilaria sinensis may help prevent or treat prostate issues by balancing hormones.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
January 2006 in “Actas Urológicas Españolas” Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.